Table 2

Summary of clinical characteristics of the group of untreated patients

Patient number*

P9

P17

P25

P32

P38

P41

P43

P45

P46

P50

P53

P61

P64

P68

Sex

F

F

F

M

F

F

F

F

F

F

F

F

F

F


CD27+IgD+ (%)

8

8

7

6

8

24

6

13

28

3

33

4

3

17

SLEDAI** score

0

0

0

0

3

0

0

0

0

0

0

0

0

0

SLICC*** score

0

0

1

0

1

2

1

0

0

5

0

0

1

0

Disease manifestations****:

Joint

x

x

x

x

x

x

x

x

x

x

x

x

Mucocutaneous

x

x

x

x

x

x

x

x

x

CNS involvement

x

x

Renal involvement

x

x

x

Hematologic

x

Serositis

x

x


(*) Patients' numbers are the same as in Table 1. (**) SLEDAI, Systemic Lupus Erythematosus Disease Activity Index. (***) SLICC, "Systemic Lupus International Collaborating Clinics" damage index for SLE. Except where indicated otherwise, data were obtained at the moment of the inclusion into the study. (****) The clinical manifestations that appeared throughout the course of the disease are shown.

CNS: central nervous system

Rodríguez-Bayona et al. Arthritis Research & Therapy 2010 12:R108   doi:10.1186/ar3042

Open Data